Skip to main content
Premium Trial:

Request an Annual Quote

Silence Cleared to Test Cancer Drug in Pancreatic Cancer


Silence Therapeutics said this week that it has received clearance from German regulators to start a phase Ib/IIa clinical trial of its lead cancer drug Atu027 in combination with the widely prescribed chemotherapeutic gemcitabine for pancreatic cancer.

The company said that the first portion of the study will take approximately three months to complete, and the phase IIa portion about a year. The entire trial is expected to wrap up in mid-2014.

Silence also said that the regulators suggested that the drug combination be tested in a “wide range of cancers, and that such trials could be run in parallel with the pancreatic cancer study.

Atu027, which comprises blunt-ended siRNAs targeting the protein kinase PKN-3, recently finished a phase I dose-finding trial in patients with advanced or metastatic solid tumors.

In June, Silence said that preliminary data from the study indicate that 0.336 mg/kg is the maximum tolerated dose of the drug, and that treatment at 0.18 mg/kg achieved the same blood plasma siRNA concentration that in preclinical studies triggered PKN3 silencing.

Silence also said this week that it is “actively looking for an aggressive expansion” of its technology platform, which includes a stable of drug-delivery approaches, drug targets, and key personnel.

“The company and its major shareholders are reviewing the financing options in respect of this expansion,” Silence said, noting that it has roughly £8 million ($12 million) on hand.

Company officials did not return a request for additional comment.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.